CN111084780A - Application of geraniin in preparing medicine for treating osteoporosis and fracture - Google Patents
Application of geraniin in preparing medicine for treating osteoporosis and fracture Download PDFInfo
- Publication number
- CN111084780A CN111084780A CN202010023863.6A CN202010023863A CN111084780A CN 111084780 A CN111084780 A CN 111084780A CN 202010023863 A CN202010023863 A CN 202010023863A CN 111084780 A CN111084780 A CN 111084780A
- Authority
- CN
- China
- Prior art keywords
- fracture
- geraniin
- osteoporosis
- bone
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 87
- 239000003814 drug Substances 0.000 title claims abstract description 55
- JQQBXPCJFAKSPG-SVYIMCMUSA-N Geraniin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2[C@@H]3OC(=O)C=4C=C(O)C(O)=C5O[C@@]6(O)C(=O)C=C([C@@H](C5=4)C6(O)O)C(=O)O[C@H]4[C@@H]3OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@H]4O2)=C1 JQQBXPCJFAKSPG-SVYIMCMUSA-N 0.000 title abstract description 93
- 229920000061 Geraniin Polymers 0.000 title abstract description 91
- GJMUCSXZXBCQRZ-UHFFFAOYSA-N geraniin Natural products Oc1cc(cc(O)c1O)C(=O)OC2OC3COC(=O)c4cc(O)c(O)c(O)c4c5cc(C(=O)C67OC3C(O6)C2OC(=O)c8cc(O)c(O)c9OC%10(O)C(C(=CC(=O)C%10(O)O)C7=O)c89)c(O)c(O)c5O GJMUCSXZXBCQRZ-UHFFFAOYSA-N 0.000 title abstract description 87
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000011575 calcium Substances 0.000 claims abstract description 30
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 30
- 235000001465 calcium Nutrition 0.000 claims description 29
- 229960005069 calcium Drugs 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 15
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- 229930003316 Vitamin D Natural products 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 235000001055 magnesium Nutrition 0.000 claims description 5
- 239000011777 magnesium Substances 0.000 claims description 5
- 229910052749 magnesium Inorganic materials 0.000 claims description 5
- 229940091250 magnesium supplement Drugs 0.000 claims description 5
- 235000019166 vitamin D Nutrition 0.000 claims description 5
- 239000011710 vitamin D Substances 0.000 claims description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 5
- 229940046008 vitamin d Drugs 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 230000037406 food intake Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 229940055726 pantothenic acid Drugs 0.000 claims description 3
- 235000019161 pantothenic acid Nutrition 0.000 claims description 3
- 239000011713 pantothenic acid Substances 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000208152 Geranium Species 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 33
- 230000035876 healing Effects 0.000 abstract description 27
- 230000037182 bone density Effects 0.000 abstract description 24
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract description 16
- 208000010392 Bone Fractures Diseases 0.000 description 105
- 206010017076 Fracture Diseases 0.000 description 100
- 210000002966 serum Anatomy 0.000 description 31
- 210000001672 ovary Anatomy 0.000 description 23
- 238000001514 detection method Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 206010010149 Complicated fracture Diseases 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000011084 recovery Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 13
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 13
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 13
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 13
- 229940074393 chlorogenic acid Drugs 0.000 description 13
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 13
- 235000001368 chlorogenic acid Nutrition 0.000 description 13
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 229940116852 myricetin Drugs 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 11
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 11
- 235000007743 myricetin Nutrition 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 235000013824 polyphenols Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000005526 G1 to G0 transition Effects 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 244000038594 Phyllanthus urinaria Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 206010020649 Hyperkeratosis Diseases 0.000 description 4
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 4
- 206010037802 Radius fracture Diseases 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 229930189596 geraniinic acid Natural products 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000000825 ultraviolet detection Methods 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012982 microporous membrane Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002786 Corilagin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000221017 Euphorbiaceae Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000037118 bone strength Effects 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- TUSDEZXZIZRFGC-XIGLUPEJSA-N corilagin Chemical compound O([C@H]1[C@H](O)[C@H]2OC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC[C@@H](O1)[C@H]2O)C(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-XIGLUPEJSA-N 0.000 description 2
- CPWYQGWOJMNXGJ-UHFFFAOYSA-N corilagin Natural products OC1C2COC(=O)c3c(O)c(O)c(O)c(O)c3c4c(O)c(O)c(O)c(O)c4C(=O)OC1C(O)C(OC(=O)c5cc(O)c(O)c(O)c5)O2 CPWYQGWOJMNXGJ-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920001301 Hexahydroxydiphenic acid Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- -1 aromatics Substances 0.000 description 1
- 238000004380 ashing Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000005770 birds nest Nutrition 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 238000010262 high-speed countercurrent chromatography Methods 0.000 description 1
- 229920001461 hydrolysable tannin Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000005765 wild carrot Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of geraniin in preparing a medicine for treating osteoporosis and fracture, belongs to the technical field of biological medicine, and can promote healing of the osteoporosis and fracture, improve bone density of osteoporosis, increase fracture strength, bone ash weight and bone calcium content and reduce the risk of reoccurrence of fracture. The invention also provides a medicine for treating osteoporosis complicated with fracture, which comprises geraniin; the medicine is administered in an amount of 1-200mg/kg geraniin per day, 1 or 2-4 times per day, and is administered in a manner of 9-12 weeks or more of intake.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of geraniin in preparation of a medicine for treating osteoporosis and fracture.
Background
Osteoporosis (OP) is a degenerative disease of the systemic bone tissue structure, and the elderly are predisposed to this disease. OP is a high risk factor of fracture, the incidence rate of OP combined fracture of the population over 60 years old is about 12.2 percent, the aging pace of the population in China is accelerated, the number of fracture cases caused by OP is increased year by year, the life health of the old is seriously threatened, and heavy burden is brought to families and society. Because OP is a progressive disease, the risk of re-fracture is high even after fracture healing if effective control therapy is not available. At present, the osteoporosis is mainly prevented and treated by the following aspects: preventing dietary calcium deficiency and vitamin D3 of special people in childhood, juvenile, gestation, etc., and controlling risk factors of morbidity; the early diagnosis of the disease is carried out through biochemical examination and bone imaging examination of serum bone-derived phosphatase, osteocalcin and the like; for patients with confirmed diagnosis, the patients are treated by changing living habits, supplementing sufficient calcium and vitamin D3 through diet control and applying medicines; the operation treatment is carried out on the patient with the damaged bone shape and structure. The existing treatment methods use bisphosphonates, estrogens, parathyroid hormone, calcitonin and vitamin D3 drugs singly or jointly, so that the treatment effects are better, but the defects of large toxic and side effects, inconvenient use of some drugs and the like exist, and the application of the drugs is limited to a certain extent.
Geraniin is extracted from Phyllanthus urinaria L (Euphorbiaceae), and has chemical structure shown in figure 1, and recent research shows that Geraniin has multiple pharmacological activities: (1) the in vivo and in vitro experiments show that the geraniin can eliminate oxygen free radicals, hydroxyl free radicals, superoxide free radicals and the like. (2) And (3) tumor resistance: geraniin can inhibit activity of transforming growth factor, etc., and can scare tumor migration, invasion, and decrease anti-apoptosis ability, inhibit tumor growth, and even accelerate tumor cell apoptosis. (3) Antiviral and antibacterial activity. The application of geraniin in treating osteoporosis complicated with fracture has not been reported.
Disclosure of Invention
The invention aims to provide application of geraniin in preparing a medicine for treating osteoporosis and fracture, wherein the geraniin can promote healing of the fracture, improve bone density of osteoporosis, increase fracture strength, bone ash weight and bone calcium content, and reduce the risk of reoccurrence of fracture.
The technical scheme adopted by the invention for realizing the purpose is as follows:
application of Geraniin in preparing medicine for treating osteoporosis complicated with fracture is provided. The geraniin has strong therapeutic effect on osteoporosis and combined fracture, can promote the union of combined fracture, improve the bone density of osteoporosis, improve fracture breaking force, bone ash weight and bone calcium content, reduce the risk of secondary fracture, and has small adverse reaction on the geraniin for treating osteoporosis and combined fracture patients.
According to one embodiment of the present invention, the geraniin is a geraniin monomer and/or a geraniin salt.
The invention also aims to provide a medicine for treating osteoporosis combined fracture, which comprises geraniin.
According to an embodiment of the invention, the medicament further comprises one or more agents selected from the group consisting of: vitamin C, vitamin A, vitamin D, vitamin B1, vitamin B2, vitamin B6, pantothenic acid, folic acid, calcium and magnesium. Preferably, the medicament further comprises vitamin D and calcium.
According to an embodiment of the invention, the medicament further comprises a pharmaceutically acceptable carrier and/or excipient and/or diluent.
According to an embodiment of the invention, the medicament is an oral composition.
Still another object of the present invention is to provide a method for treating osteoporosis complicated with fracture, which comprises the steps of: the medicament is applied in an amount of 1-200mg/kg geraniin per day. Preferably, administration is 1 or divided into 2-4 administrations per day.
According to one embodiment of the invention, the medicament is administered in a manner that results in an ingestion of 9-12 weeks or more.
The invention has the beneficial effects that: the geraniin has strong therapeutic effect on osteoporosis and combined fracture, can promote the union of combined fracture, improve the bone density of osteoporosis, improve fracture breaking force, bone ash weight and bone calcium content, reduce the risk of secondary fracture, and has small adverse reaction on the geraniin for treating osteoporosis and combined fracture patients.
Drawings
FIG. 1 is a chemical structural formula of Geraniin of the present invention;
FIG. 2 shows X plates of each group of animals in example 4 of the present invention.
Detailed Description
While the invention is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It is not intended to limit the invention to the particular form disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
These examples are provided only for more specifically illustrating the present invention, and it is apparent to those skilled in the art that the scope of the present invention is not limited to these examples according to the gist of the present invention.
The invention provides application of geraniin in preparing a medicine for treating osteoporosis and fracture. Osteoporosis is frequently found in the elderly, and the occurrence of osteoporotic fractures is associated with decreased bone density and mass. Once the osteoporotic fracture patient is fractured again, the patient usually needs to be kept in bed, and embolic diseases can be generated, even the patient dies. The geraniin has strong therapeutic effect on osteoporosis and combined fracture, can promote the union of combined fracture, improve the bone density of osteoporosis, improve fracture breaking force, bone ash weight and bone calcium content, reduce the risk of secondary fracture, and has small adverse reaction on the geraniin for treating osteoporosis and combined fracture patients.
In one embodiment of the present invention, the geraniin is a geraniin monomer or a geraniin salt.
In one embodiment of the present invention, the geraniin is derived from an active extract of Phyllanthus urinaria L, a plant of Euphorbiaceae.
In one embodiment of the present invention, the geraniin is obtained by the following method:
1) adding the phyllanthus urinaria powder into an extracting solution containing 0.3-1.5% of lactic acid, 20-25% of ammonium sulfate and 17-23% of ethanol according to the mass concentration of 1:10-20, extracting for 40-50min under the ultrasonic wave of 150 plus 180W, centrifuging for 5-12min at 8000 plus 15000r/min, standing and layering the supernatant in a separating funnel, and filtering through a 0.45 mu m microporous filter membrane to obtain the extracting solution; the geraniin is hydrolysable tannin, is extracted by a heating reflux method and is easily decomposed into gallic acid, hexahydroxy diphenyl dicarboxylic acid, ellagic acid, corilagin and corilagin, and the active ingredients in the plant materials can be accelerated to enter a solvent by utilizing strong vibration, high acceleration, strong cavitation effect, stirring effect and the like generated by ultrasonic waves, so that the extraction rate of the active ingredients is increased, the extraction time is shortened, and the influence of high temperature on the extracted ingredients can be avoided; meanwhile, the extracting solution can better destroy the increase of the acting force of the phenolic substances and the matrix under the lower ethanol concentration, is beneficial to the dissolution of the phenolic substances, has strong selectivity on the phenolic substances, is beneficial to the extraction of the phenolic substances in the phyllanthus urinaria powder, and ensures that the extraction rate of the phenolic substances in the phyllanthus urinaria powder can reach at least 8.4 percent;
2) preparing a solvent system from petroleum ether, ethyl acetate, methanol, ammonium citrate and water according to a volume ratio of 0.3-0.7:5-15:0.1-0.3:0.04-0.0.08:18-25, placing the solvent system into a separating funnel, shaking uniformly, standing for layering, after balancing for 1-4h, separating an upper phase from a lower phase, taking the upper phase as a stationary phase and the lower phase as a mobile phase;
3) filling the fixed phase into a column of a high-speed counter-current chromatograph at the flow rate of 10-15mL/min, then operating a main machine of the high-speed counter-current chromatograph in the forward direction at the rotating speed of 700 plus 800r/min, simultaneously pumping the mobile phase at the flow rate of 0.5-1.5mL/min, when the mobile phase begins to flow out of the chromatographic column, injecting an extracting solution which is dissolved into the mobile phase according to the mass concentration of 1-10mg/mL through an injection valve, entering a sample separation state, simultaneously setting the ultraviolet detection wavelength to be 280nm, and then collecting the geraniin fraction according to the ultraviolet spectrogram of a detector. The high-speed countercurrent chromatography (HSCCC) is a better method for separating compounds which are similar in property and easy to denature at present, the distribution coefficient of the geraniin in the solvent system used in the embodiment is proper, the geraniin can be better separated, the purity and the recovery rate of the geraniin fraction are improved, and the purity of the geraniin fraction can reach at least 94% and the recovery rate can reach at least 90% through HPLC detection. Further purifying the geraniin fraction to obtain more than 99% of pure geraniin.
The invention also provides application of the geraniin and the myricetin in preparing a medicament for treating osteoporosis complicated with fracture. Wherein the weight ratio of the geraniin to the myricetin is 1: 0.05-0.3. The geraniin and myricetin are matched to have a synergistic enhancement effect, can be used for synergistically treating osteoporosis and combined fracture symptoms of ovariectomized Japanese long-ear white rabbits, synergistically promoting the healing of combined fracture, synergistically improving bone density, fracture breaking force, bone ash weight and bone calcium content, and greatly reducing the risk of secondary fracture.
The invention also provides application of the geraniin and the chlorogenic acid in preparing the medicine for treating osteoporosis and fracture. Wherein the weight ratio of the geraniin to the chlorogenic acid is 1: 0.1-0.25. The compatibility of the geraniin and the chlorogenic acid shows a synergistic enhancement effect, can synergistically treat osteoporosis and combined fracture symptoms of the ovariectomized Japanese long-ear white rabbit, synergistically promote the healing of combined fracture, synergistically improve the bone density, the fracture strength, the bone ash weight and the bone calcium content, and greatly reduce the risk of secondary fracture.
The invention also provides a medicine for treating osteoporosis combined fracture, which comprises geraniin and/or myricetin, or comprises geraniin and/or chlorogenic acid.
In one embodiment of the present invention, the medicament further comprises one or more agents selected from the group consisting of: vitamin C, vitamin A, vitamin D, vitamin B1, vitamin B2, vitamin B6, pantothenic acid, folic acid, calcium lactate, calcium and magnesium. Preferably, the medicament further comprises vitamin D and calcium lactate.
In one embodiment of the present invention, the medicament further comprises a pharmaceutically acceptable carrier and/or excipient and/or diluent. Among the carriers, excipients, and diluents that may be included are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, and the like.
In one embodiment of the invention, the medicament is an oral composition. The medicine is in the form of powder, pill, granule, tablet, capsule, suspension, liquid, emulsion or syrup. The solid drug is produced by mixing at least one excipient, such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Furthermore, in addition to simple excipients, lubricants such as magnesium stearate, talc, and the like are also used. The liquid medicine may contain various excipients such as wetting agents, sweeteners, aromatics, preservatives, etc., in addition to conventional simple diluents such as water and liquid paraffin.
The invention also provides a use method of the medicine.
The invention also provides a use method of the medicine, wherein the medicine is applied according to the amount of 1-200mg/kg of geraniin per day. Preferably, administration is 1 or divided into 2-4 administrations per day.
In one embodiment of the invention, the drug is administered by ingestion for 9-12 weeks or more.
The present invention is further described in detail with reference to the following examples:
example 1:
the geraniin is obtained by the following method:
1) adding cacumen Securinegae Suffruticosae powder into extractive solution containing 0.8% lactic acid, 22% ammonium sulfate and 19% ethanol at a ratio of 1:14, extracting under 160W ultrasonic wave for 45min, centrifuging at 10000r/min for 8min, standing supernatant in separating funnel for layering, and filtering with 0.45 μm microporous membrane to obtain extractive solution with phenolic substance extraction rate of 8.83%;
2) preparing a solvent system from petroleum ether, ethyl acetate, methanol, ammonium citrate and water according to a volume ratio of 0.5:10:0.2:0.05:20, placing the solvent system in a separating funnel, shaking uniformly, standing for layering, after balancing for 2 hours, separating an upper phase from a lower phase, taking the upper phase as a stationary phase, and taking the lower phase as a mobile phase;
3) filling a column of a high-speed counter-current chromatograph with the stationary phase at a flow rate of 12mL/min, then operating a main machine of the high-speed counter-current chromatograph in a forward direction at a rotating speed of 750r/min, simultaneously pumping the mobile phase at a flow rate of 1.0mL/min, when the mobile phase begins to flow out of the chromatographic column, injecting an extracting solution dissolved in the mobile phase at a mass concentration of 3mg/mL through an injection valve, entering a sample separation state, simultaneously setting an ultraviolet detection wavelength to be 280nm, and then collecting geraniin fraction according to an ultraviolet spectrogram of a detector. HPLC detection shows that the purity of the geraniin fraction is 95.2%, and the recovery rate is 90.8%.
Example 2:
the geraniin is obtained by the following method:
1) adding cacumen Securinegae Suffruticosae powder into extractive solution containing 0.8% lactic acid, 22% ammonium sulfate and 19% ethanol at a ratio of 1:14, extracting under 160W ultrasonic wave for 45min, centrifuging at 10000r/min for 8min, standing supernatant in separating funnel for layering, and filtering with 0.45 μm microporous membrane to obtain extractive solution with phenolic substance extraction rate of at least 5.44%;
2) preparing a solvent system from petroleum ether, ethyl acetate, methanol and water according to the volume ratio of 0.5:10:0.2:20, placing the solvent system into a separating funnel, shaking uniformly, standing for layering, after balancing for 2 hours, separating an upper phase from a lower phase, taking the upper phase as a stationary phase, and taking the lower phase as a mobile phase;
3) filling a column of a high-speed counter-current chromatograph with the stationary phase at a flow rate of 12mL/min, then operating a main machine of the high-speed counter-current chromatograph in a forward direction at a rotating speed of 750r/min, simultaneously pumping the mobile phase at a flow rate of 1.0mL/min, when the mobile phase begins to flow out of the chromatographic column, injecting an extracting solution dissolved in the mobile phase at a mass concentration of 3mg/mL through an injection valve, entering a sample separation state, simultaneously setting an ultraviolet detection wavelength to be 280nm, and then collecting geraniin fraction according to an ultraviolet spectrogram of a detector.
Comparing example 1 with example 2, it is clear that the extraction rate of polyphenol is higher in example 1 than in example 2, which shows that the extraction rate of polyphenol can be improved by the extract liquid in example 1.
Example 3:
the geraniin is obtained by the following method:
1) adding cacumen Securinegae Suffruticosae powder into extractive solution containing 0.8% lactic acid, 22% ammonium sulfate and 19% ethanol at a ratio of 1:14, extracting under 160W ultrasonic wave for 45min, centrifuging at 10000r/min for 8min, standing supernatant in separating funnel for layering, and filtering with 0.45 μm microporous membrane to obtain extractive solution;
2) preparing a solvent system from petroleum ether, ethyl acetate, methanol and water according to the volume ratio of 0.5:10:0.2:20, placing the solvent system into a separating funnel, shaking uniformly, standing for layering, after balancing for 2 hours, separating an upper phase from a lower phase, taking the upper phase as a stationary phase, and taking the lower phase as a mobile phase;
3) filling a column of a high-speed counter-current chromatograph with the stationary phase at a flow rate of 12mL/min, then operating a main machine of the high-speed counter-current chromatograph in a forward direction at a rotating speed of 750r/min, simultaneously pumping the mobile phase at a flow rate of 1.0mL/min, when the mobile phase begins to flow out of the chromatographic column, injecting an extracting solution dissolved in the mobile phase at a mass concentration of 3mg/mL through an injection valve, entering a sample separation state, simultaneously setting an ultraviolet detection wavelength to be 280nm, and then collecting geraniin fraction according to an ultraviolet spectrogram of a detector. HPLC detection shows that the purity of the geraniin fraction is 89.7%, and the recovery rate is 82.5%.
Comparing example 1 with example 2, it can be seen that the distribution coefficient of geraniin in the solvent system used in example 1 is appropriate, so that the geraniin can be well separated, and the purity and recovery rate of the geraniin fraction can be improved.
Example 4:
influence of geraniin on bone density and fracture healing of osteoporosis and fracture-complicated Japanese Long-ear white rabbit
1. Experimental animals:
healthy and clean grade female Japanese long-ear white rabbits, weighing 2-2.5kg, were provided by the laboratory animal center of Kunming medical college [ laboratory animal experimental production license number: SCXK (Dian.) 2015 + 0002 ]. Feeding conditions are as follows: the temperature is 22 +/-5 ℃, the relative temperature is 60-70%, a single cage is used for feeding only one single cage, the complete beverage is fed, the feeding is carried out once a day, and the automatic drinking device is used for freely drinking water.
2. Molding die
2.1 replication of the osteoporosis model: an experimental rabbit bilateral ovarian ablation replication osteoporosis model is used for simulating human postmenopausal osteoporosis. After the experimental rabbits were adaptively raised for three weeks, animals were anesthetized by 1ml/kg body weight with 3% sodium pentobarbital by otic intravenous injection, fixed in the supine position, 3cm unhaired along each side of the ventral midline under 2/3, the operative area was sterilized with iodophor and deiodinated with ethanol twice, and the skin and peritoneum were incised along the ventral midline with a 3cm long incision. The operator stretches into the front of the pelvis to find the uterus, finds the uterine horns on two sides forwards along the uterus and pulls the uterine horns to the wound, and then lifts the oviduct along the uterine horns to find the ovary. The suspensory ligament of the ovary was isolated blunt and the ovary was lifted out of the abdominal wall incision. A small hole is formed on the ovary mesentery close to the ovary blood vessel, 3 hemostats are used for clamping the ovary and the surrounding tissues, one of the hemostats is close to the ovary, the other two hemostats are far away from the ovary, then the ovary mesentery and the blood vessel are cut off by ligating at the position 2mm outside the far-end hemostat of the ovary by using a suture, and the ovary is removed. Observing whether bleeding exists or not, and if bleeding exists, performing second ligation at the position just clamped to stop bleeding; the bird nest is returned to the abdominal cavity without bleeding. The normal control group did not remove the ovary, only removed part of the adipose tissue around the ovary, and the rest of the surgery methods were consistent. Closing the incision after removing both ovaries, and suturing peritoneum and abdominal wall muscles by using a round needle and a No. 7 surgical thread; the skin was sutured with a triangular needle and 7 gauge thread. After the iodophor is disinfected, the operation is finished, the reaction of animals is observed after the operation, and if infection occurs, ceftriaxone can be injected into the abdominal cavity to resist the infection.
2.2 fracture model replication: the experimental animals are anesthetized by injecting 3% sodium pentobarbital into ear vein according to 1ml/kg body weight, fixed in a lying position, the fur of the left front limb wound bone part is removed, the skin is cut, the wound bone is separated, a part of the wound bone is removed by using a bone wire saw to form the wound bone fracture with the width of 2mm and the depth of 1/2 diameters, and the osteoporosis and fracture animal model is formed. The incision was closed and the periosteum and skin were sutured separately. The model group and the treatment group were cut open the skin and made fracture models, and the normal control group was cut open only the skin and isolated the surrounding bone without making fracture.
3. Experimental grouping and treatment
30 Japanese Long-ear white rabbits were randomly divided into 3 groups of normal control group, osteoporosis-complicated fracture model group, osteoporosis-complicated fracture +10 mg/kg-d Geraniin treatment group, and each group had 10 rabbits. The osteoporosis model and the 10 mg/kg-d geraniin treatment group animals are copied by a method of removing ovaries by surgery, and fat tissues around the ovaries are removed by surgery in a normal control group for pseudo surgery. 3 months after the osteoporosis model is copied, when the animals without ovaries have osteoporosis and the bone density is obviously different from the normal contrast, the fracture model copying is carried out on the 10mg/kg d geraniin model group and the treatment group to form an osteoporosis and fracture model. Immediately after operation, the treatment group is treated by administering geraniin 10mg/kg every day, and after feeding for 10 weeks, serum biochemical index detection, X-ray detection and bone recovery index detection are carried out.
4. Analysis of results
4.1 serum Biochemical index detection
Serum calcium, phosphorus, alkaline phosphatase are common indicators for assessing bone formation and bone turnover. The serum alkaline phosphatase, serum calcium and phosphorus concentrations are measured by a full-automatic biochemical analyzer, the results are shown in table 1, compared with a sham operation group, the serum alkaline phosphatase, serum calcium and serum phosphorus levels of a model control group and a treatment group are increased, the increase of the treatment group is obvious, and the intervention of the geraniin has a promotion effect on the quality of fracture healing.
TABLE 1 Biochemical indexes of serum of osteoporosis and fracture groups
| Group of | Alkaline phosphatase (U/L) | Serum calcium (mmol/L) | Serum phosphorus (mmol/L) |
| Normal control group | 81.94±7.19 | 2.70±0.21 | 1.57±0.15 |
| Model control group | 83.08±7.03 | 2.23±0.18 | 2.00±0.14 |
| Treatment group | 83.76±8.47ab | 2.43±0.26ab | 2.07±0.14ab |
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
4.2X-ray detection
The fracture healing condition of osteoporosis complicated fracture rat is observed by X plain film (as shown in figure 2, wherein A is normal control group, B is model control group, and C is geraniin treatment group), and as can be seen from figure 2, after 10 weeks of treatment of 10 mg/kg. d geraniin, the fracture healing of the treatment group is obvious, the fracture healing score is obviously increased, but fracture lines can still be seen. And the fracture healing score is carried out according to the scoring table shown in the table 2, the scoring result is shown in the table 3, and it can be seen that after 10 weeks of treatment of 10 mg/kg. d geraniin, the fracture healing score of the osteoporosis complicated fracture rat is higher, and compared with the model control group, the difference has statistical significance.
TABLE 2 fracture heal score-table
| X-ray representation | Value of credit |
| No callus shadow was found on the |
0 |
| Callus shadow can be seen on the X-ray film, and the fracture line is relatively fuzzy | 1 |
| With obvious callus growth and obvious blurring of fracture lines | 2 |
| Has abundant callus growth and nearly disappeared fracture line | 3 |
| The fracture line disappears, is completely connected and approaches ossification | 4 |
TABLE 3 osteoporosis with fracture rat fracture healing score
| Group of | Fracture healing score |
| |
0 |
| Model control group | 3.160±0.259 |
| Treatment group | 4.390±0.197b |
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
4.3 bone recovery index detection
The bone density is an important index reflecting the bone strength, and is measured by a dual-energy X-ray bone density measuring instrument; the fracture force of the fracture is measured by a bone strength meter in a three-point fracture square way; the weight of the bone ash is measured after ashing for 2 hours at 800 ℃ by adopting a muffle furnace; the calcium and magnesium concentration in the supernatant is determined after the bone ash is dissolved by hydrochloric acid, and the corresponding calcium and magnesium content in the bone is calculated. The bone recovery indexes of animals in each group of osteoporosis and combined fracture are shown in table 4, after 10-week treatment of 10 mg/kg. d geraniin, the fracture force of the left radius, the weight of the bone ash of the left radius, the bone calcium content and the bone density are obviously increased, and compared with a model control group, the difference has statistical significance, which shows that the bone density is increased after the geraniin is dried.
TABLE 4 osteoporosis recovery index for animal groups with fracture
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
Example 5:
effect of Geraniin and myricetin on bone density and fracture healing of osteoporosis and fracture-complicated Japanese Long-ear white rabbit
1. Experimental animals: as in example 4.
2. Molding: as in example 4.
3. Experimental grouping and treatment
Japanese Long-ear white rabbits were randomly divided into 5 groups of a normal control group, an osteoporosis-complicated fracture model group, an osteoporosis-complicated fracture +10 mg/kg-d Geraniin treatment group 1, an osteoporosis-complicated fracture +2.0 mg/kg-d myricetin treatment group 2, and an osteoporosis-complicated fracture +10 mg/kg-d Geraniin +2.0 mg/kg-d myricetin treatment group 3, each group consisting of 10 rabbits. The osteoporosis model, treatment 1 group, treatment 2 group and treatment 3 group animals adopt a method of removing ovaries by surgery to duplicate the osteoporosis model, and fat tissues around the ovaries are removed by surgery in a normal control group to carry out a pseudo surgery. 3 months after the osteoporosis model is copied, when the animals without ovaries have osteoporosis and the bone density is obviously different from the normal contrast, the fracture model copying is carried out on the 10mg/kg d geraniin model group and the treatment group to form an osteoporosis and fracture model. Immediately after the operation, the treatment of 1 group of the patients starts to be treated by 10mg/kg of geraniin every day, the treatment of 2 groups of the patients starts to be treated by 2.0mg/kg of d-myricetin every day, the treatment of 3 groups of the patients starts to be treated by 10mg/kg of geraniin and 2.0mg/kg of d-myricetin every day, and the serum biochemical index detection, the X-ray detection and the bone recovery index detection are carried out after the patients are fed for 10 weeks.
4. Compatibility calculation method
Calculating the q value according to the formula of King, wherein q is equal to EA+B/(EA+EB-EA×EB) And is used for judging whether the effect of the two medicines after being used in a matching way is better than that of single administration. If q is<0.55, the two medicines have obvious antagonism; q is not less than 0.55<0.85, the two medicines have antagonistic action; q is not less than 0.85<1.15, the two medicines have the functions of simple addition; q is not less than 1.15<20, the two medicines have synergistic effect; q is not less than20, the effects of the two medicines are obviously enhanced.
5. Analysis of results
5.1 serum Biochemical index detection
The results of the measurement of serum alkaline phosphatase, serum calcium and phosphorus concentrations are shown in table 5, and compared with the model control group, the serum alkaline phosphatase, serum calcium and serum phosphorus levels in the 1 treatment group and the 3 treatment groups are increased obviously, which shows that the intervention of geraniin has a promoting effect on the quality of fracture healing and the effect of the combined medicine of geraniin and myricetin in the 3 treatment groups is better.
TABLE 5 serum biochemical indices of osteoporosis with fracture
| Group of | Alkaline phosphatase (U/L) | Serum calcium (mmol/L) | Serum phosphorus (mmol/L) |
| Normal control group | 81.94±7.19 | 2.70±0.21 | 1.57±0.15 |
| Model control group | 83.08±7.03 | 2.23±0.18 | 2.00±0.14 |
| Treatment 1 group | 83.76±8.47ab | 2.43±0.26ab | 2.07±0.14ab |
| Treatment of 2 groups | 82.24±5.35ab | 2.25±0.19ab | 1.93±0.12ab |
| Treatment of 3 groups | 86.55±8.47ab | 2.56±0.26ab | 2.24±0.14ab |
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
5.2X-ray detection
The fracture healing condition of the osteoporosis-complicated fracture rat is observed by adopting an X plain film, the fracture healing scoring is carried out according to the scoring table shown in table 2, the scoring result is shown in table 6, and after 10 weeks of treatment, compared with a model control group, the fracture healing scoring of the osteoporosis-complicated fracture rat of 1 group, 2 groups and 3 groups is higher and the effect of 3 groups is optimal, which shows that the compatibility of geraniin and myricetin in the 3 groups can synergistically treat osteoporosis-complicated fracture symptoms of the ovary-removed Japanese Long-ear white rabbit, and synergistically promote the union of the complicated fracture.
TABLE 6 osteoporosis Co-fracture rat fracture healing score
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
4.3 bone recovery index detection
After 10 weeks of treatment, the bone recovery indexes of animals with osteoporosis and fracture in each group are shown in table 7, compared with a model control group, the bone density of the radius in the treatment 1 group, the treatment 2 group and the treatment 3 group is respectively increased by 16.91%, 4.83% and 26.57%, according to a King's formula, q is 26.57%/(16.91% + 4.83% -16.91% × 4.83%) is 1.27 (shown in table 7), and q is more than or equal to 1.15 and less than or equal to 20, which indicates that the compatibility of geraniin and myricetin has a synergistic effect on increasing the bone density of the radius. Meanwhile, as can be seen from table 7, compared with the model control group, the left radius fracture force, the left radius bone ash weight, the bone calcium content and the L3 lumbar vertebrae density of the radius of the treatment groups 1, 2 and 3 are obviously increased, and q of the left radius fracture force, the left radius bone ash weight, the bone calcium content and the L3 lumbar vertebrae density of the treatment groups 3 are respectively 1.20, 1.65, 1.29 and 2.10 and are consistent with q being more than or equal to 1.15 and less than 20, which indicates that the compatibility of geraniin and myricetin in the treatment groups 3 is synergistic, the bone density, the bone fracture strength, the bone ash weight and the bone calcium content are synergistically increased, and the risk of bone fracture reoccurrence is greatly reduced.
TABLE 7 osteoporosis recovery index for animals with osteoporosis and fracture
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
Example 6:
effect of Geraniin and chlorogenic acid on bone density and fracture healing of osteoporosis and fracture-complicated Japanese Long-ear white rabbit
1. Experimental animals: as in example 4.
2. Molding: as in example 4.
3. Experimental grouping and treatment
Japanese Long-ear white rabbits were randomly divided into 5 groups of a normal control group, an osteoporosis combined fracture model group, an osteoporosis combined fracture +10 mg/kg-d geraniin treatment group 1, an osteoporosis combined fracture +1.8 mg/kg-d chlorogenic acid treatment group 2, and an osteoporosis combined fracture +10 mg/kg-d geraniin +1.8 mg/kg-d chlorogenic acid treatment group 3, each group consisting of 10 rabbits. The osteoporosis model, treatment 1 group, treatment 2 group and treatment 3 group animals adopt a method of removing ovaries by surgery to duplicate the osteoporosis model, and fat tissues around the ovaries are removed by surgery in a normal control group to carry out a pseudo surgery. 3 months after the osteoporosis model is copied, when the animals without ovaries have osteoporosis and the bone density is obviously different from the normal contrast, the fracture model copying is carried out on the 10mg/kg d geraniin model group and the treatment group to form an osteoporosis and fracture model. Immediately after operation, the treatment of 1 group is started to be treated by 10mg/kg geraniin every day, the treatment of 2 groups is started to be treated by 1.8mg/kg d chlorogenic acid every day, the treatment of 3 groups is started to be treated by 10mg/kg geraniin and 1.8mg/kg d chlorogenic acid every day, and after 10 weeks, the biochemical index detection, the X-ray detection and the bone restoration index detection of the blood serum are carried out.
4. The compatibility calculation method comprises the following steps: as in example 5.
5. Analysis of results
5.1 serum Biochemical index detection
The results of the measurement of the serum alkaline phosphatase, the serum calcium and the serum phosphorus concentrations are shown in table 8, compared with the model control group, the serum alkaline phosphatase, the serum calcium and the serum phosphorus levels in the treatment 1 group and the treatment 3 groups are increased obviously, which shows that the intervention of the geraniin has a promoting effect on the quality of fracture healing and the effect of the combined medicine of the geraniin and the chlorogenic acid in the treatment 3 groups is better.
TABLE 8 serum biochemical index of osteoporosis and fracture
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
5.2X-ray detection
The fracture healing condition of the osteoporosis-complicated fracture rat is observed by adopting an X plain film, the fracture healing scoring is carried out according to the scoring table shown in table 2, the scoring result is shown in table 9, and after 10 weeks of treatment, compared with a model control group, the fracture healing scoring of the osteoporosis-complicated fracture rat in 1 group, 2 groups and 3 groups is higher and the effect of 3 groups is optimal, which shows that the compatibility of geraniin and chlorogenic acid in the 3 groups can synergistically treat osteoporosis-complicated fracture symptoms of the ovary-removed Japanese long-ear white rabbit, and synergistically promote the union of the complicated fracture.
TABLE 9 osteoporosis Co-fracture rat fracture healing score
| Group of | Fracture healing score |
| |
0 |
| Model control group | 3.160±0.259 |
| Treatment 1 group | 4.390±0.197b |
| Treatment of 2 groups | 3.243±0.156b |
| Treatment of 3 groups | 4.690±0.163b |
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
4.3 bone recovery index detection
After 10 weeks of treatment, the bone recovery indexes of animals in each group of osteoporosis-complicated fracture are shown in table 10, compared with a model control group, the bone density of the radius in the treatment 1 group, the treatment 2 group and the treatment 3 group is respectively increased by 16.91%, 2.41% and 24.25%, according to a King's formula, q is 24.25%/(16.91% + 2.41% -16.91% × 2.41%) is 1.28 (shown in table 10), and the result accords with that q is more than or equal to 1.15 and less than or equal to 20, which indicates that the compatibility of the geraniin and the chlorogenic acid has a synergistic effect on increasing the bone density of the radius. Meanwhile, as can be seen from table 10, compared with the model control group, the left radius fracture force, the left radius bone ash weight, the bone calcium content and the L3 lumbar vertebrae density of the radius of the treatment groups 1, 2 and 3 are obviously increased, and q of the left radius fracture force, the left radius bone ash weight, the bone calcium content and the L3 lumbar vertebrae density of the treatment groups 3 are respectively 1.25, 1.88, 1.62 and 1.63 and are all consistent with q being more than or equal to 1.15 and less than or equal to 20, which indicates that the compatibility of geraniin and chlorogenic acid in the treatment groups 3 is synergistic, the bone density, the bone fracture force, the bone calcium content are synergistically increased, and the risk of bone fracture reoccurrence is greatly reduced.
TABLE 10 osteoporosis recovery index for animal groups with fracture
Note: a represents the statistical difference from the normal control group (P <0.05), and b represents the statistical difference from the model control group (P < 0.05).
Conventional techniques in the above embodiments are known to those skilled in the art, and therefore, will not be described in detail herein.
The above embodiments are merely illustrative, and not restrictive, and those skilled in the art can make various changes and modifications without departing from the spirit and scope of the invention. Therefore, all equivalent technical solutions also belong to the scope of the present invention, and the protection scope of the present invention should be defined by the claims.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010023863.6A CN111084780A (en) | 2020-01-09 | 2020-01-09 | Application of geraniin in preparing medicine for treating osteoporosis and fracture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010023863.6A CN111084780A (en) | 2020-01-09 | 2020-01-09 | Application of geraniin in preparing medicine for treating osteoporosis and fracture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111084780A true CN111084780A (en) | 2020-05-01 |
Family
ID=70399039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010023863.6A Pending CN111084780A (en) | 2020-01-09 | 2020-01-09 | Application of geraniin in preparing medicine for treating osteoporosis and fracture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111084780A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984326A (en) * | 2022-06-02 | 2022-09-02 | 中国科学院大学宁波华美医院 | A kind of multiple cross-linked injectable bone repair hydrogel preparation material and preparation method thereof |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1378858A (en) * | 2002-04-23 | 2002-11-13 | 中国科学院昆明植物研究所 | Medicine for preventing or treating osteoporosis and its preparing process and application |
| US20030139354A1 (en) * | 2000-06-02 | 2003-07-24 | Herwig Buccholz | Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases |
| JP2004244327A (en) * | 2003-02-12 | 2004-09-02 | Ichimaru Pharcos Co Ltd | Bleaching agent and bleaching cosmetic |
| CN1720040A (en) * | 2002-12-05 | 2006-01-11 | 宝生物工程株式会社 | Remedy |
| KR20070093226A (en) * | 2006-03-13 | 2007-09-18 | 한국 한의학 연구원 | Osteoporosis and fracture prevention and treatment composition comprising a mixed herbal medicine extract |
| CN101522183A (en) * | 2006-08-02 | 2009-09-02 | 秋久俊博 | Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as acti |
| US20110038960A1 (en) * | 2008-04-21 | 2011-02-17 | Herbonis Ag | Preparation and use of a plant extract from solanum glaucophyllum with an enriched content of 1,25-dihydroxyvitamin d3 glycosides and quercetin glycosides |
| US20110076345A1 (en) * | 2007-04-02 | 2011-03-31 | Alfredo Avila | Herbal Formulation for the Treatment of Bone Fractures and Osseous Defects |
| CN102065914A (en) * | 2008-04-15 | 2011-05-18 | 埃泰克斯公司 | Minimal Invasive Treatment of the Spine (MITV) Using Calcium Phosphate Combination Bone Cement |
| CN103211855A (en) * | 2013-03-29 | 2013-07-24 | 北京本草通汇科技中心 | Application of Eucommia ulmoides xylem in preparation of health-care product |
| CN103989694A (en) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第四军医大学 | Application of myricetrin for preventing and treating osteoporosis |
| CN105939721A (en) * | 2013-12-02 | 2016-09-14 | 塞尔巴有限公司 | Herbal combinations for treatment of a skin condition |
| CN107115568A (en) * | 2017-02-23 | 2017-09-01 | 温州生物材料与工程研究所 | Self assembly lysozyme multilayer membrane preparation method with antibiotic property and biocompatibility |
| BR102018003389A2 (en) * | 2018-02-21 | 2019-09-10 | Universidade Federal Do Ceará | herbal preparations with anti-inflammatory and antiviral activity from standardized extract of spondias mombin l. |
| CN110691630A (en) * | 2017-08-02 | 2020-01-14 | 巴斯夫美容护理法国公司 | Use of rambutan peel extract for moisturizing skin and/or mucous membranes |
| CN111526735A (en) * | 2017-12-27 | 2020-08-11 | 三得利控股株式会社 | Composition for improving intestinal barrier function |
-
2020
- 2020-01-09 CN CN202010023863.6A patent/CN111084780A/en active Pending
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030139354A1 (en) * | 2000-06-02 | 2003-07-24 | Herwig Buccholz | Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases |
| CN1378858A (en) * | 2002-04-23 | 2002-11-13 | 中国科学院昆明植物研究所 | Medicine for preventing or treating osteoporosis and its preparing process and application |
| CN1720040A (en) * | 2002-12-05 | 2006-01-11 | 宝生物工程株式会社 | Remedy |
| JP2004244327A (en) * | 2003-02-12 | 2004-09-02 | Ichimaru Pharcos Co Ltd | Bleaching agent and bleaching cosmetic |
| KR20070093226A (en) * | 2006-03-13 | 2007-09-18 | 한국 한의학 연구원 | Osteoporosis and fracture prevention and treatment composition comprising a mixed herbal medicine extract |
| CN101522183A (en) * | 2006-08-02 | 2009-09-02 | 秋久俊博 | Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as acti |
| US20110076345A1 (en) * | 2007-04-02 | 2011-03-31 | Alfredo Avila | Herbal Formulation for the Treatment of Bone Fractures and Osseous Defects |
| CN102065914A (en) * | 2008-04-15 | 2011-05-18 | 埃泰克斯公司 | Minimal Invasive Treatment of the Spine (MITV) Using Calcium Phosphate Combination Bone Cement |
| US20110038960A1 (en) * | 2008-04-21 | 2011-02-17 | Herbonis Ag | Preparation and use of a plant extract from solanum glaucophyllum with an enriched content of 1,25-dihydroxyvitamin d3 glycosides and quercetin glycosides |
| CN103211855A (en) * | 2013-03-29 | 2013-07-24 | 北京本草通汇科技中心 | Application of Eucommia ulmoides xylem in preparation of health-care product |
| CN105939721A (en) * | 2013-12-02 | 2016-09-14 | 塞尔巴有限公司 | Herbal combinations for treatment of a skin condition |
| CN103989694A (en) * | 2014-05-29 | 2014-08-20 | 中国人民解放军第四军医大学 | Application of myricetrin for preventing and treating osteoporosis |
| CN107115568A (en) * | 2017-02-23 | 2017-09-01 | 温州生物材料与工程研究所 | Self assembly lysozyme multilayer membrane preparation method with antibiotic property and biocompatibility |
| CN110691630A (en) * | 2017-08-02 | 2020-01-14 | 巴斯夫美容护理法国公司 | Use of rambutan peel extract for moisturizing skin and/or mucous membranes |
| CN111526735A (en) * | 2017-12-27 | 2020-08-11 | 三得利控股株式会社 | Composition for improving intestinal barrier function |
| BR102018003389A2 (en) * | 2018-02-21 | 2019-09-10 | Universidade Federal Do Ceará | herbal preparations with anti-inflammatory and antiviral activity from standardized extract of spondias mombin l. |
Non-Patent Citations (5)
| Title |
|---|
| RONG PING ZHOU，等: "Chlorogenic Acid Prevents Osteoporosis by Shp2/PI3K/Akt Pathway in Ovariectomized Rats", PLOS ONE, vol. 11, no. 12, pages 1 - 3 * |
| 张小超，等: "老鹳草素调控家兔骨质疏松性骨折关键基因Cbfα1 的表达", 《昆明医科大学学报》 * |
| 张小超，等: "老鹳草素调控家兔骨质疏松性骨折关键基因Cbfα1 的表达", 《昆明医科大学学报》, vol. 39, no. 8, 15 August 2018 (2018-08-15), pages 1 * |
| 张小超，等: "老鹳草素调控家兔骨质疏松性骨折关键基因Cbfα1 的表达", 昆明医科大学学报, vol. 39, no. 8, pages 1 * |
| 甘宁，等: "杨梅素减轻去卵巢大鼠骨质疏松", 第三军医大学学报, vol. 38, no. 6, pages 614 - 618 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984326A (en) * | 2022-06-02 | 2022-09-02 | 中国科学院大学宁波华美医院 | A kind of multiple cross-linked injectable bone repair hydrogel preparation material and preparation method thereof |
| CN114984326B (en) * | 2022-06-02 | 2023-12-05 | 中国科学院大学宁波华美医院 | A multiple cross-linked injectable bone repair hydrogel preparation material and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7706025B2 (en) | Preparation for treating and/or preventing polycystic ovary syndrome and method for producing same | |
| CN111084780A (en) | Application of geraniin in preparing medicine for treating osteoporosis and fracture | |
| CN109045162B (en) | Traditional Chinese medicine composition for treating endometriosis and application thereof | |
| EP4205734B1 (en) | Alpha-asarone for use in the treatment of hemorrhagic stroke | |
| CN101744955B (en) | Drug for treatment of ischemic cerebrovascular disease | |
| CN101890062A (en) | Application of nard pine and its extract in the preparation of medicine for treating gastric ulcer | |
| AU2007205284A1 (en) | Herbal compositions for treating or preventing climacteric symptoms and use thereof | |
| CN119365200A (en) | Compounds and compositions for treating bleeding disorders | |
| EP3962471B1 (en) | Composition for the prevention and treatment of urinary stones | |
| US11517602B2 (en) | Traditional Chinese medicine composition for improving bone health and preparation and uses thereof | |
| CN119745844B (en) | Application of cinnamaldehyde in preparation of medicine for improving pregnant woman iron deficiency anemia and bad pregnancy outcome | |
| CN1168462C (en) | An oral solution capable of lowering blood fat and improving symptoms of myocardial ischemia and myocardial infarction | |
| CN105560857A (en) | Traditional Chinese medicine preparation capable of improving contrast effect of digestive tract | |
| US11058737B2 (en) | Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females | |
| CN110448562A (en) | Application of the lupenone in preparation treatment renal damage drug | |
| KR20220003696A (en) | New use of melatonin | |
| CN111000886B (en) | A kind of pharmaceutical composition for treating ischemic stroke and its application | |
| RU2812129C1 (en) | Hormonal agent for regulating sexual heat in small domestic animals | |
| CN112891366B (en) | Traditional Chinese medicine active ingredient formula for treating postmenopausal osteoporosis and application thereof | |
| CN1062475C (en) | Styptic for gynaecology | |
| EP4568689A1 (en) | Compositions and use in methods for treating a cognitive deficit | |
| CN119950584A (en) | Chinese medicinal Polygonum aviculare and Chinese medicinal composition and application thereof in preparing medicine for preventing and treating vascular diseases | |
| CN118453669A (en) | Application of armillaria mellea in preparation of medicines for preventing and treating bone metabolism or osteoporosis and armillaria mellea preparation | |
| RU2192271C1 (en) | Method of cardiotropic agent preparing | |
| CN105106533A (en) | Traditional Chinese medicine composition for treating gestational gallstones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |